Clinical Trials

Non-Muscle Invasive Bladder Neoplasms

NCT06834074 2026-05-14

NVL-655-EAP

Temporarily not available

Carcinoma, Non-Small-Cell Lung

NCT04830202 2026-05-13

Expanded Access to Telisotuzumab Vedotin

Carcinoma, Non-Small-Cell Lung

NCT04571229 2026-05-11

Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma

Osteosarcoma

NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Neurofibromatoses, Neurofibroma, Plexiform

NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Desmoid Tumors

NCT06915766 2026-05-08

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT06948955 2026-05-08

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT07573215 2026-05-07

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Pancreatic Neoplasms

NCT05572970 2026-05-06

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Tumor-Agnostic

Neoplasms

NCT07535359 2026-05-06

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

Small Cell Lung Carcinoma

NCT06761976 2026-05-05

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Tumor-Agnostic

Neoplasms

NCT07560709 2026-05-01

Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma

Osteosarcoma

NCT01916148 2026-04-27

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

Endocrine

Beckwith-Wiedemann Syndrome, Hyperinsulinism, Hypoglycemia, Insulinoma, Congenital Hyperinsulinism

NCT07536815 2026-04-27

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

Breast

Triple Negative Breast Neoplasms

NCT05511714 2026-04-24

Expanded Access [11C] Methionine PET Imaging

CNSHead & Neck

Head and Neck Neoplasms, Central Nervous System Neoplasms

NCT05593185 2026-04-24

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Leukemia, Lymphoma

NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Dermatologic

Melanoma

NCT04085653 2026-04-14

Managed Access Programs for BYL719, Alpelisib

Breast

Breast Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT01163383 2026-04-13

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Neuroblastoma

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Breast

Breast Neoplasms

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Non-Muscle Invasive Bladder Neoplasms

NCT05776134 2026-04-08

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT07502716 2026-03-31

Compassionate Use of Ubamatamab

NCT07497984 2026-03-27

ITM11 Expanded Access Program

Meningioma

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04507503 2026-03-10

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing

Cholangiocarcinoma

NCT04091295 2026-03-04

BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Chordoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Neurofibrosarcoma

NCT06404034 2026-03-04

Expanded Access to Gallium Maltolate (GaM)

Glioblastoma

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT06799221 2026-02-27

Expanded Access Program for OOS Obe-cel

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06836648 2026-02-25

Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer

Prostatic Neoplasms

NCT03581240 2026-02-20

An Intermediate Expanded Use Trial of DFMO

Typical Teratoid Rhabdoid Tumor, Medulloblastoma, Neuroblastoma, Neuroectodermal Tumors, Primitive

NCT07399015 2026-02-18

Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC

Anophthalmia with pulmonary hypoplasia, Pancreatic Neoplasms

NCT06797362 2026-02-17

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Carcinoma, Non-Small-Cell Lung

NCT05346835 2026-02-13

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Plasma cell

Multiple Myeloma

NCT06439966 2026-02-12

Expanded Access to ABBV-787

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06617572 2026-02-09

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Sarcoma, Synovial, Liposarcoma, Myxoid

NCT05982873 2026-02-06

Expanded Access to Telisotuzumab Adizutecan

Other solid neoplasm

Solid Tumors

NCT03123029 2026-01-30

Expanded Access to Venetoclax

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06195514 2026-01-30

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Neoplasms

NCT07310277 2026-01-29

Expanded Access to ABBV-706

Small Cell Lung Carcinoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT00590915 2026-01-23

EMTP

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03756311 2026-01-23

Expanded Access to NanoPac